TL;DR
Researchers have identified two specific "lipid-rich" macrophage subpopulations ($TREM2^{high}$ and $MARCO^{high}$) that accumulate in the transition zone of enlarged human prostates. These cells move beyond the traditional M1/M2 activation model and actively drive prostate cell proliferation, suggesting that targeting immune-driven lipid metabolism could be a new therapeutic frontier for Benign Prostatic Hyperplasia (BPH).
What Problem Does This Paper Address?
Benign Prostatic Hyperplasia (BPH) is a near-universal condition in aging men, leading to lower urinary tract symptoms (LUTS) that significantly impact quality of life. While clinicians have long observed chronic inflammation in BPH tissues, the "who" and "how" of this inflammation remained murky.
The field has traditionally relied on a simplistic M1 (pro-inflammatory) vs. M2 (anti-inflammatory/repair) binary to describe macrophage activation. However, this model often fails to capture the complexity of chronic disease. The authors sought to define the specific macrophage "states" associated with increasing prostate size and determine if these cells are merely bystanders or active drivers of the tissue overgrowth (hyperplasia) that characterizes the disease.
Methods
The study employed a multi-omic approach to map the immune landscape of the human prostate:
- Single-cell RNA-seq (scRNA-seq): The team analyzed over 100,000 CD45+ leukocytes from the transition zones of 20 patients—10 with "large" prostates (>90g) and 10 with "small" prostates (<40g).
- RNA Velocity Analysis: Using tools like
scVeloandCellRank, the researchers modeled the "trajectories" of these cells to understand how they transition between different functional states. - Flow Cytometry & Immunofluorescence: These were used to validate the transcriptomic findings and physically locate the macrophages within the prostate stroma.
- Functional In Vitro Assays: To move from correlation to causation, the authors used THP-1 derived macrophages loaded with lipids (oleic acid or cholesterol) and co-cultured them with prostate epithelial and stromal cell lines to measure their effect on cell growth.
Datasets
The primary dataset is a newly generated scRNA-seq atlas of human BPH leukocytes, which the authors have made available via GEO (accession GSE269205). They also utilized existing marker sets for macrophage polarization and compared their findings to macrophage subsets identified in other inflammatory diseases, such as rheumatoid arthritis.
Key Insights and Ideas
- The M1/M2 Paradigm is Insufficient: The study found that BPH macrophages do not fit neatly into the M1 or M2 boxes. Instead, the cells that preferentially accumulate in large prostates belong to a "neither" category, characterized by unique metabolic signatures.
- Lipid Metabolism as a Driver: The most significant finding was the identification of $TREM2^{high}$ and $MARCO^{high}$ macrophage clusters. These cells are "lipid-rich," showing upregulated pathways for lipid uptake and processing.
- Metabolic-Immune Crosstalk: These lipid-rich macrophages aren't just sitting there; they appear to be "stable" end-states. RNA velocity analysis suggests these cells are less likely to transition into other types as the prostate grows, effectively becoming a permanent fixture in the inflammatory microenvironment.
- Correlation with Clinical Severity: The abundance of these specific macrophages positively correlates with both patient Body Mass Index (BMI) and International Prostatic Symptom Scores (IPSS), linking cellular biology directly to patient experience.
Key Results
- Myeloid Dominance: While several immune cell types change, myeloid cells (macrophages) are the primary contributors to the increased leukocyte count in large prostates.
- Significant Accumulation: $TREM2^{high}$ and $MARCO^{high}$ clusters showed a statistically significant increase in large vs. small prostates (FDR = $1.5 \times 10^{-4}$).
- Direct Proliferation Boost: In co-culture experiments, macrophages loaded with oleic acid significantly increased the proliferation of both prostate epithelial cells ($p=0.0138$) and stromal fibroblasts ($p=0.0027$) compared to control macrophages.
- Lipid Loading Validation: Flow cytometry confirmed that $TREM2^{high}$ macrophages have significantly higher neutral lipid content (measured by BODIPY staining) than their $TREM2^{low}$ counterparts ($p=0.0254$).
Limitations and Future Work
The authors acknowledge several limitations:
- Sample Size: While 20 patients is robust for scRNA-seq, it remains a relatively small cohort for broader clinical generalizations.
- Cell Models: The in vitro work relied on THP-1 cells (a leukemia-derived line), which may not perfectly replicate the behavior of primary human tissue-resident macrophages.
- Ontogeny: It is still unclear whether these lipid-rich cells are recruited from the blood or are resident cells that "flip" their metabolic switch locally.
Future Directions: The study opens the door for "immunometabolic" therapies. If these $TREM2^{high}$ cells are the engines of prostate growth, targeting lipid metabolism pathways or using specific immune modulators (like TNF-antagonists, currently in clinical trials) could provide a more targeted alternative to current BPH medications.
Summary updated